Rami Habib

Jul 2, 2024 | acrjournals.onlinelibrary.wiley.com | Rami Habib |Roya M. Dayam |Carol Hitchon |Vinod Chandran

INTRODUCTION Although we are recovering from the COVID-19 pandemic, SARS-CoV-2 remains a public health threat,1 particularly for those taking immunosuppressants for immune-mediated inflammatory disorders (IMIDs), such as inflammatory bowel disease (IBD), psoriasis (including psoriatic arthritis [PsO/PsA]), rheumatoid arthritis (RA), spondylarthritis (SpA), and systemic lupus erythematosus (SLE).2-5 Serological responses (eg, anti-Spike [S] or anti–receptor binding domain [RBD]) to COVID-19...